Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04TKG
|
|||
| Former ID |
DNC009447
|
|||
| Drug Name |
LUFFARIELLOLIDE
|
|||
| Synonyms |
Luffariellolide; 111149-87-2; 3-[(3E,7E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohexen-1-yl)deca-3,7-dienyl]-2-hydroxy-2H-furan-5-one; AC1NTS09; CHEMBL451037; SCHEMBL10422020; MolPort-044-561-235; NSC622149; AKOS025294086; NSC-622149; SMP2_000178; RT-013604; C19901; J-002531; 4-((3E,7E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-enyl)deca-3,7-dienyl)-5-hydroxyfuran-2(5H)-one; 2(5H)-Furanone, 4-(4,8-dimethyl-10-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3,7-decadienyl)-5-hydroxy-, (E,E)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H38O3
|
|||
| Canonical SMILES |
CC1=C(C(CCC1)(C)C)CCC(=CCCC(=CCCC2=CC(=O)OC2O)C)C
|
|||
| InChI |
1S/C25H38O3/c1-18(11-7-13-21-17-23(26)28-24(21)27)9-6-10-19(2)14-15-22-20(3)12-8-16-25(22,4)5/h10-11,17,24,27H,6-9,12-16H2,1-5H3/b18-11+,19-10+
|
|||
| InChIKey |
JPWPYTMXSXYUPG-QZPYEDBESA-N
|
|||
| CAS Number |
CAS 111149-87-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Group IIA phospholipase A2 (GIIA sPLA2) | Target Info | Inhibitor | [1] |
| BioCyc | Phospholipases | |||
| KEGG Pathway | Glycerophospholipid metabolism | |||
| Ether lipid metabolism | ||||
| Arachidonic acid metabolism | ||||
| Linoleic acid metabolism | ||||
| alpha-Linolenic acid metabolism | ||||
| Metabolic pathways | ||||
| Ras signaling pathway | ||||
| Vascular smooth muscle contraction | ||||
| Pancreatic secretion | ||||
| Fat digestion and absorption | ||||
| Pathway Interaction Database | Glypican 1 network | |||
| Reactome | Acyl chain remodelling of PC | |||
| Acyl chain remodelling of PE | ||||
| Acyl chain remodelling of PI | ||||
| WikiPathways | Cardiac Hypertrophic Response | |||
| Glycerophospholipid biosynthesis | ||||
| Glycerophospholipid Biosynthetic Pathway | ||||
| Spinal Cord Injury | ||||
| Eicosanoid Synthesis | ||||
| MicroRNAs in cardiomyocyte hypertrophy | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phospholipase A2 inhibitors from marine organisms. J Nat Prod. 1992 Dec;55(12):1701-17. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.